Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration

Core Insights - Dren Bio has entered a new collaboration with Sanofi SA, building on their existing relationship following Sanofi's acquisition of Dren Bio's DR-0201 program for deep B-cell depletion [1][2] Collaboration Details - The collaboration focuses on the discovery and development of a next-generation B-cell depleting therapy for autoimmune diseases [2] - Dren Bio will receive an upfront payment of $100 million and could earn up to $1.7 billion in development, regulatory, and commercial milestone payments [3] - The companies will work together on discovery and preclinical development, utilizing Dren Bio's proprietary platform [3] Development Responsibilities - After selecting a development candidate, Sanofi will take over the responsibilities for development, manufacturing, regulatory, and commercialization efforts [4] - Dren Bio has the option to enter a U.S. profit/loss sharing arrangement, co-funding 40% of ongoing global development costs in exchange for U.S. co-promotion rights and a 50/50 share of U.S. profits and losses [4] Financial Incentives - Dren Bio will also be eligible for milestones and tiered royalties on net sales outside the U.S. [5] - Sanofi's stock is currently down 2.87% at $47.29 [5]